MdxHealth (TM) : MDxHealth Collaborates with HistoGeneX to offer Pharmaco Molecular Diagnostic Services

  MdxHealth (TM) : MDxHealth Collaborates with HistoGeneX to offer Pharmaco
                        Molecular Diagnostic Services

IRVINE, CA,  LIEGE  and ANTWERP,  BELGIUM  - 8:00  AM  CET, July  16,  2013  - 
MDxHealth SA (NYSE  Euronext: MDXH)  and HistoGeneX N.V.  today announced  the 
commencement of a  Pharmaco Molecular Diagnostic  services collaboration.  The 
collaboration enables MDxHealth  to combine its  epigenetic technologies  with 
HistoGeneX's well-established  pharmaco  diagnostic  services  to  provide  to 
pharmaceutical companies and oncologists with integrated molecular  diagnostic 
testing services. HistoGeneX's  laboratory in Belgium  will also perform  MGMT 
service testing on behalf of MDxHealth's current and future clients.

"This collaboration with MDxHealth allows  us to introduce epigenetic  testing 
technologies to our pharmaceutical and oncology clients, further expanding our
molecular capabilities and menu," said Dr. Mark Kockx, CEO of HistoGeneX.  "We 
take pride in offering the most current, cutting-edge diagnostic methodologies
to our  clients and  believe that  the MGMT  test, combined  with  MDxHealth's 
next-generation sequencing capabilities, adds significant value."

"The collaboration with HistoGenex  further broadens our PharmacoMDx  services 
on a global  basis and  expands upon our  biomarker discovery  program at  the 
Center of  Pharmaco (epi)Genomics,  a  joint-venture with  Ghent  University," 
stated Dr. Jan Groen, CEO of  MDxHealth. "HistoGeneX has established a  strong 
reputation  in  the  pharma  industry,  combining  their  Belgium-based   CLIA 
certified laboratory services and expansive  test menu with our US-based  CLIA 
laboratory  and   Next  Gen   epigenetic   capabilities,  will   enable   both 
organizations to  leverage  our respective  networks,  and grow  our  customer 

MDxHealth's PharmacoMDx solutions leverage Next-Generation and Deep Sequencing
technologies for the  discovery of  effective individualized  epigenetic-based 
diagnostic and  personalized  therapeutic products.  The  identification  and 
validation of epigenetic biomarkers are playing an increasingly important role
in the development process of  new compounds and companion diagnostics.  With 
the recent completion of a multinational phase III study using its proprietary
MGMT methylation  test, and  numerous completed  and ongoing  Phase I  and  II 
clinical trials, MDxHealth has demonstrated biomarker development and clinical
trials management capabilities within the pharmaceutical community

About HistoGeneX
HistoGeneX  is  a  molecular  pathology  company  offering  a  wide  range  of 
histology, pathology and molecular diagnostic services for pharmaceutical  and 
hospital clients, including extensive biobanking capabilities, clinical  trial 
diagnostics and research services. HistoGeneX was established in 2001 and  has 
built  an  impressive  track  record  offering  contract  diagnostics.  As  a 
testimony  to  HistoGeneX's  dedication   to  quality,  major   pharmaceutical 
companies have worked with HistoGeneX over the past years to generate clinical
testing data as part of their regulatory submission packages and files for  CE 

About MDxHealth^®
MDxHealth is a molecular diagnostics company that develops and  commercializes 
advanced epigenetic tests for cancer assessment and the personalized treatment
of  patients.  The  company's  first  commercial  product,  ConfirmMDx^TM  for 
Prostate Cancer,  has been  shown  to help  distinguish  patients who  have  a 
true-negative biopsy  from those  who may  have undetected  cancer.  MDxHealth 
helps to address  a large  and growing unmet  medical need  for better  cancer 
diagnosis and treatment  information. The company  has a proprietary  platform 
and a  strong  epigenetic  product  pipeline focused  on  the  development  of 
products for prostate, brain and lung cancers. The company is based in Irvine,
California  with  a  European  headquarters   in  Liege,  Belgium.  For   more 
information visit MDxHealth's website at

Contacts :

MDxHealth            MDxHealth Media Contact HistoGeneX
Dr. Jan Groen        Mike Sinclair           Dr. Mark Kockx
CEO                  Halsin Partners         CEO
US: +1 949 812 6979  UK: +44 20 7318 2955    BE : +32 3 218 10 85
BE: +32 4 364 20 70  Cell: +44 7968 022075

This press  release contains  forward-looking  statements and  estimates  with 
respect to the anticipated future performance  of MDxHealth and the market  in 
which it operates. Such statements and estimates are based on assumptions  and 
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable  but may  not prove to  be correct.  Actual events  are 
difficult to predict, may  depend upon factors that  are beyond the  company's 
control, and  may turn  out to  be materially  different. MDxHealth  expressly 
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in  its expectations with regard thereto or  any 
change in events, conditions or circumstances  on which any such statement  is 
based unless  required by  law or  regulation. This  press release  does  not 
constitute an offer or  invitation for the sale  or purchase of securities  or 
assets of MDxHealth  in any jurisdiction.  No securities of  MDxHealth may  be 
offered or sold within the United  States without registration under the  U.S. 
Securities Act  of  1933, as  amended,  or  in compliance  with  an  exemption 
therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are  trademarks 
or registered trademarks  of MDxHealth  SA. All other  trademarks and  service 
marks are the property of their respective owners.

To access the PDF version, please click here


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: MdxHealth (TM) via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.